Literature DB >> 10718926

Adrenoceptor subtype involvement in suppression of prolactin secretion by noradrenaline.

K L Colthorpe1, J Nalliah, S T Anderson, J D Curlewis.   

Abstract

In sheep, injection of noradrenaline suppresses prolactin secretion by a direct effect at the pituitary gland. The aims of this study were to use primary cultures of ovine pituitary cells to examine the receptor subtypes that mediate the inhibitory effect of noradrenaline on prolactin secretion and, by using receptor antagonists in vivo, determine whether noradrenaline acts as a prolactin release-inhibiting factor (PIF). Noradrenaline and dopamine suppressed prolactin secretion from ovine pituitary cells with ED50s of 60.9+/-46.6 and 1.5+/-1.0x10-9 mol/l, respectively (P<0.05). The in-vitro prolactin release-inhibiting effect of noradrenaline (10-7 mol/l) was not blocked by the dopamine antagonists pimozide (D2) or SCH23390 (D1) but was blocked by each of the adrenoceptor antagonists (alpha1-adrenoceptor antagonists prazosin and WB4101, the alpha2-adrenoceptor antagonist yohimbine and the beta-adrenoceptor antagonist propranolol). The response to adrenoceptor agonists was also tested in vitro. The alpha1-adrenoceptor agonists phenylephrine and cirazoline significantly suppressed prolactin. Of the alpha2-agonists, clonidine had no effect whereas oxymetazoline and p-aminoclonidine both suppressed prolactin. The beta-adrenoceptor agonist isoproterenol also suppressed prolactin while the specific beta3-antagonist BRL37344 had no effect. When the adrenoceptor antagonists were tested in vivo in ewes manipulated to be in the luteal phase, only WB4101 significantly (P<0.05) increased plasma prolactin concentrations but this response was small and only observed in one of two experiments. In summary, these experiments suggest that adrenoceptors and not dopamine receptors are responsible for the inhibitory effect of noradrenaline on prolactin secretion in vitro but do not implicate a particular adrenoceptor subtype. The in-vivo experiments do not provide convincing evidence for a role for noradrenaline as a physiologically important PIF.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10718926     DOI: 10.1046/j.1365-2826.2000.00450.x

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  4 in total

1.  Lactotroph functional activity in hypothalamic dopaminergic system insufficiency.

Authors:  L K Dil'mukhametovaa; T S Pronina; G Z Ziyazetdinova; N E Vorob'eva; Yu V Nikolenko; A N Krasnov; S G Georgievac; M V Ugryumova
Journal:  Dokl Biol Sci       Date:  2010 Jan-Feb

2.  Hormonal responses in athletes: the use of a two bout exercise protocol to detect subtle differences in (over)training status.

Authors:  R Meeusen; M F Piacentini; B Busschaert; L Buyse; G De Schutter; J Stray-Gundersen
Journal:  Eur J Appl Physiol       Date:  2003-10-02       Impact factor: 3.078

3.  Effectiveness in Block by Dexmedetomidine of Hyperpolarization-Activated Cation Current, Independent of Its Agonistic Effect on α2-Adrenergic Receptors.

Authors:  Te-Ling Lu; Te-Jung Lu; Sheng-Nan Wu
Journal:  Int J Mol Sci       Date:  2020-11-30       Impact factor: 5.923

Review 4.  Effective Perturbations by Small-Molecule Modulators on Voltage-Dependent Hysteresis of Transmembrane Ionic Currents.

Authors:  Sheng-Nan Wu; Chao-Liang Wu; Hsin-Yen Cho; Chi-Wu Chiang
Journal:  Int J Mol Sci       Date:  2022-08-21       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.